ADIAL PHARMACEUTICALS INC (ADIL) Stock Fundamental Analysis
NASDAQ:ADIL - Nasdaq - US00688A2050 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to ADIL. ADIL was compared to 198 industry peers in the Pharmaceuticals industry. While ADIL seems to be doing ok healthwise, there are quite some concerns on its profitability. ADIL is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year ADIL has reported negative net income.
ADIL had a negative operating cash flow in the past year.
In the past 5 years ADIL always reported negative net income.
In the past 5 years ADIL always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of ADIL (-261.65%) is worse than 91.41% of its industry peers.
ADIL has a worse Return On Equity (-324.41%) than 73.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -261.65% | ||
| ROE | -324.41% | ||
| ROIC | N/A |
ROA(3y)-197.33%
ROA(5y)-210.06%
ROE(3y)-279.33%
ROE(5y)-332.84%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ADIL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for ADIL has been increased compared to 1 year ago.
Compared to 5 years ago, ADIL has more shares outstanding
There is no outstanding debt for ADIL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -24.67, we must say that ADIL is in the distress zone and has some risk of bankruptcy.
ADIL's Altman-Z score of -24.67 is on the low side compared to the rest of the industry. ADIL is outperformed by 86.36% of its industry peers.
ADIL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -24.67 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ADIL has a Current Ratio of 4.16. This indicates that ADIL is financially healthy and has no problem in meeting its short term obligations.
ADIL's Current ratio of 4.16 is fine compared to the rest of the industry. ADIL outperforms 64.14% of its industry peers.
ADIL has a Quick Ratio of 4.16. This indicates that ADIL is financially healthy and has no problem in meeting its short term obligations.
ADIL has a Quick ratio of 4.16. This is in the better half of the industry: ADIL outperforms 65.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.16 | ||
| Quick Ratio | 4.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 55.09% over the past year.
EPS 1Y (TTM)55.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, ADIL will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.34% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.16%
EPS Next 2Y17.34%
EPS Next 3Y14.82%
EPS Next 5Y18.34%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ADIL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADIL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ADIL's earnings are expected to grow with 14.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.34%
EPS Next 3Y14.82%
5. Dividend
5.1 Amount
No dividends for ADIL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.65
-0.04 (-5.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners9.87%
Inst Owner Change0%
Ins Owners1.33%
Ins Owner Change0%
Market Cap4.27M
Analysts80
Price Target6.63 (920%)
Short Float %10.61%
Short Ratio0.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.52%
Min EPS beat(2)9.7%
Max EPS beat(2)15.33%
EPS beat(4)2
Avg EPS beat(4)-16.82%
Min EPS beat(4)-84.19%
Max EPS beat(4)15.33%
EPS beat(8)4
Avg EPS beat(8)5.29%
EPS beat(12)7
Avg EPS beat(12)10.16%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.33%
PT rev (3m)-13.33%
EPS NQ rev (1m)2.94%
EPS NQ rev (3m)-23.75%
EPS NY rev (1m)-31.82%
EPS NY rev (3m)-31.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.05 | ||
| P/tB | 1.05 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.94
EYN/A
EPS(NY)-1.78
Fwd EYN/A
FCF(TTM)-1.05
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0
BVpS0.62
TBVpS0.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -261.65% | ||
| ROE | -324.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-197.33%
ROA(5y)-210.06%
ROE(3y)-279.33%
ROE(5y)-332.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.16 | ||
| Quick Ratio | 4.16 | ||
| Altman-Z | -24.67 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.07%
EPS Next Y8.16%
EPS Next 2Y17.34%
EPS Next 3Y14.82%
EPS Next 5Y18.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.7%
OCF growth 3YN/A
OCF growth 5YN/A